| Literature DB >> 19503836 |
Ashwin Dixit1, Scott F Carroll, Salman T Qureshi.
Abstract
During the latter half of the twentieth century, fungal pathogens such as Cryptococcus neoformans were increasingly recognized as a significant threat to the health of immune compromised populations throughout the world. Until recently, the closely related species C. gattii was considered to be a low-level endemic pathogen that was confined to tropical regions such as Australia. Since 1999, C. gattii has emerged in the Pacific Northwest region of North America and has been responsible for a large disease epidemic among generally healthy individuals. The changing epidemiology of C. gattii infection is likely to be a consequence of alterations in fungal ecology and biology and illustrates its potential to cause serious human disease. This review summarizes selected biological and clinical aspects of C. gattii that are particularly relevant to the recent North American outbreak and compares these to the Australian and South American experience.Entities:
Year: 2009 PMID: 19503836 PMCID: PMC2686104 DOI: 10.1155/2009/840452
Source DB: PubMed Journal: Interdiscip Perspect Infect Dis ISSN: 1687-708X
C. gattii virulence factors and their functions.
| Factor | Function |
|---|---|
| Capsule and its associated polysaccharides | Evasion of
phagocytosis [ |
| Reduction of antigen
presentation [ | |
| Reduction of
cytokine production [ | |
| Induction of
suppressor T-cells which inhibit cell-mediated immunity [ | |
| Inhibition of T-cell
responses by GXM [ | |
| Inhibition of leukocyte migration into inflammatory sites by GXM [ | |
|
| |
| Melanin | Protection against
UV radiation [ |
| Protection against
oxygen and nitrogen free radicals [ | |
| May contribute to central nervous system tropism [ | |
| Contributes to
negative cellular charge [ | |
|
| |
| Mannitol | Suggested increase
in intracranial pressure [ |
| Protection against
stress [ | |
| Protection against
oxygen free radicals [ | |
|
| |
| Extracellular protease | Proteolytic activity
[ |
| May contribute to
degradation of proteins involved in tissue integrity and host immunity [ | |
|
| |
| Products of laccase pathway | Diphenol oxidation [ |
| Synthesis of melanin
[ | |
| Degradation of wood
lignin [ | |
|
| |
| Superoxide dismutase | Protection against
oxidative stress [ |
| Protection against
oxidative burst produced by immune effector cells [ | |
|
| |
| Phospholipases | Tissue invasion via
degradation of mammalian membrane lipids and lung surfactant [ |
|
| |
| Urease | Exact function is
unknown [ |
| May aid in transfer
of | |
|
| |
| STE1 | Upregulation leads
to synthesis of diphenol oxidase (which is a laccase) [ |
|
| |
| Growth at physiological temperature (37°C) | Survival and
persistence in the host [ |
|
| |
| Tolerance of low pH | Survival and
persistence in the environment [ |
|
| |
| Tolerance of elevated salt | Survival and
persistence in the environment [ |
|
| |
| Phenotypic switching | Change in capsule
size—mucoid variant more virulent, smooth variant
suggested to be able to cross blood-brain barrier [ |
Summary of case reports of C. gattii infection.
| Age (sex) | Residence | Exposure | Health conditions | Symptoms | Pathology (molecular type) | |
|---|---|---|---|---|---|---|
|
| 47 (M) | BC mainland (on coast north of VI) | Yard/landscaping work at residence | Chronic hepatitis C, drug addiction | Cough, chills, night sweats, nausea, muscular pain, headache, appetite loss, stiff neck | Lung/brain nodules (VGI) |
|
| ||||||
|
| 48 (F) | BC (lower mainland) | Deforestation near residence, yard work, last visited VI 4 years ago | None | Dyspnea, fever, chills, headache, night sweats, appetite loss, nausea, muscular pain | Lung mass (VGIIa) |
|
| ||||||
|
| 73 (F) | BC | Little outdoor exposure, last visited VI 14 years ago | Chronic renal failure, lung disease, breast cancer, hip surgery | None | Lung nodule (VGIIa) |
|
| ||||||
|
| 59 (M) | OR | No travel out of OR in last year | Scarred lung tissue (due to occupation) | Cough, dyspnea, fever, chills, nausea, weight loss, muscular pain | Not specified (VGIIa) |
|
| ||||||
|
| 87 (M) | OR | Travel to parts of OR, WA & CO | Chronic lymphocytic leukemia (oral steroid) | Fever, weight loss, appetite loss | Meningitis (VGIIb) |
|
| ||||||
|
| 74 (M) | WA (Puget Sound) | Travel to south CA and HI in last year | Large granular lymphocytic leukemia (steroid and hormone) | Cough | Lung nodule (VGIIa) |
|
| ||||||
|
| 45 (F) | Alberta | Holidays spent on southeast shore of VI, park visits | None | Headache, blurred vision, photosensitivity, nausea, vomiting, cough | Lung opacities, airspace disease, meningitis (not specified) |
|
| ||||||
|
| 51 (M) | Denmark | Travel to Victoria and VI east coast for 7 days, garden visits | Psoriatic gout (nonsteroidal anti-inflammatory drug) | Chest pain, fever, cough, dyspnea | 3 large nodular infiltrates (VGIIa) |
|
| ||||||
|
| 54 (M) | Not specified | Not specified | Bradycardia, acute myocardial infarction, smoker | None | Lung opacity (not specified) |
|
| ||||||
|
| 62 (M) | Not specified | Not specified | Previous smoker | Chest pain | Lung nodules (not specified) |
|
| ||||||
|
| 69 (F) | Not specified | Exposure to tuberculosis | Previous smoker, total colectomy due to ulcerative colitis | Cough, dyspnea | Cavitary lesion (not specified) |
|
| ||||||
|
| 65 (M) | Not specified | Occupational (painter) | Previous smoker, mild recurrent hemoptysis | Not specified | Lung opacity, meningitis (not specified) |
Legend: BC: British Columbia, CA: California, CO: Colorado, HI: Hawaii, OR: Oregon, VI: Vancouver Island, WA: Washington.